Details for 2018815624
Up to date per 05.04.2026
Actions
Details for 2018815624
Granted/Registered
European Patent
14.10.2020 A
02.02.2022 B1
04.12.2017
US
201762594184 P
22.03.2018
US
201862646553 P
10.04.2018
US
201862655568 P
09.05.2018
US
201862669095 P
04.10.2018
US
201862741313 P
25.10.2018
US
201862750595 P
A61K 31/28 20060101AFI20190614BHEP
Owner
Alexion Pharmaceuticals, Inc.121 Seaport Boulevard Boston, MA 02210US
Representative
Representative
Häupl & Ellmeyer KG, PatentanwaltskanzleiMariahilfer Straße 50 (Kirchengasse 1)1070 WienAT
Inventor
ALA, Aftabc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
BJARTMAR, Carlc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
WEISS, Karl-Heinzc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
SCHILSKY, Michaelc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
ASKARI, Frederickc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
CZLONKOWSKA, Annac/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
FERENCI, Peterc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
HEDERA, Peterc/o Wilson Therapeutics AB Kungsgatan 3 111 43 StockholmSE
Information about Fees